Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF
· Webinar will be held today at 15:00 CET (9:00 am EST) · Digital therapeutics expert Jessica Shull joins Vicore to drive DTx program Gothenburg, May 4, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the signing of an agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the “Alex DTx Platform”. Vicore will hold a webinar at 15:00 CET (9 AM EST) today to outline